Vyzulta™

Drug - Vyzulta™ (latanoprostene bunod) [Bausch & Lomb Inc.]

July 2018

Therapeutic area - Ophthalmics, Glaucoma

Approval criteria

Patient must be 17 years old or older AND
Patient must have a diagnosis of open-angle glaucoma or ocular hypertension AND
Patient must not have known hypersensitivity to latanoprostene bunod or its derivatives (e.g., latanoprost) AND
Patient must have an adequate 6-month trial and failure of at least 1 preferred ophthalmic beta blocker agent (e.g., timolol) AND 6-month trial and failure of at least one preferred prostaglandin analogue (e.g.,latanoprost or Travatan/Travatan Z)

Patient must continue to meet the above criteria AND
Patient must have documented efficacy as defined by a decrease in intraocular pressure AND
Patient must not have experienced any treatment-restricting adverse effects (e.g., significant conjunctival hyperemia, eye irritation, eye pain, and instillation site pain)

MHCP Provider Call Center 651-431-2700 or 800-366-5411